155 related articles for article (PubMed ID: 24492687)
1. Effects of alogliptin in chronic kidney disease patients with type 2 diabetes.
Sakai Y; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Otsuka T; Ohno D; Murasawa T; Tsuruoka S
Intern Med; 2014; 53(3):195-203. PubMed ID: 24492687
[TBL] [Abstract][Full Text] [Related]
2. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial.
Ferreira JP; Mehta C; Sharma A; Nissen SE; Rossignol P; Zannad F
BMC Med; 2020 Jun; 18(1):165. PubMed ID: 32493335
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
Nakamura Y; Inagaki M; Shimizu T; Fujita K; Inoue M; Gotoh H; Oguchi K; Goto Y
Nephron Clin Pract; 2013; 123(1-2):46-51. PubMed ID: 23774306
[TBL] [Abstract][Full Text] [Related]
4. Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.
Ohashi N; Tsuji N; Naito Y; Iwakura T; Isobe S; Ono M; Fujikura T; Tsuji T; Sakao Y; Yasuda H; Kato A; Fujigaki Y
Med Sci Monit; 2014 Apr; 20():587-93. PubMed ID: 24717767
[TBL] [Abstract][Full Text] [Related]
5. Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
Keating GM
Drugs; 2015 May; 75(7):777-96. PubMed ID: 25855222
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
7. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Cornel JH; Bakris GL; Stevens SR; Alvarsson M; Bax WA; Chuang LM; Engel SS; Lopes RD; McGuire DK; Riefflin A; Rodbard HW; Sinay I; Tankova T; Wainstein J; Peterson ED; Holman RR;
Diabetes Care; 2016 Dec; 39(12):2304-2310. PubMed ID: 27742728
[TBL] [Abstract][Full Text] [Related]
8. Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.
Masuda K; Aoki K; Kamiko K; Takihata M; Ito Y; Nagakura M; Kawasaki S; Akema N; Hasegawa M; Nakajima S; Shinoda K; Toumura S; Tsunoda S; Enomoto H; Shimotomai H; Terauchi Y
Expert Opin Pharmacother; 2013 Jun; 14(9):1111-8. PubMed ID: 23600363
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care.
Metsärinne K; Bröijersen A; Kantola I; Niskanen L; Rissanen A; Appelroth T; Pöntynen N; Poussa T; Koivisto V; Virkamäki A;
Prim Care Diabetes; 2015 Feb; 9(1):31-8. PubMed ID: 25066820
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J
Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
[TBL] [Abstract][Full Text] [Related]
11. Alogliptin benzoate for management of type 2 diabetes.
Saisho Y
Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
[TBL] [Abstract][Full Text] [Related]
13. Renal function markers and metformin eligibility.
Tavares Bello C; Castro Fonseca R; Sousa Santos F; Sequeira Duarte J; Azinheira J; Vasconcelos C
Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease.
Kato S; Fukui K; Kirigaya H; Gyotoku D; Iinuma N; Kusakawa Y; Iguchi K; Nakachi T; Iwasawa T; Kimura K
Int J Cardiol; 2016 Nov; 223():770-775. PubMed ID: 27573605
[TBL] [Abstract][Full Text] [Related]
15. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Mita T; Katakami N; Yoshii H; Onuma T; Kaneto H; Osonoi T; Shiraiwa T; Kosugi K; Umayahara Y; Yamamoto T; Yokoyama H; Kuribayashi N; Jinnouchi H; Gosho M; Shimomura I; Watada H;
Diabetes Care; 2016 Jan; 39(1):139-48. PubMed ID: 26628419
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
Takeuchi K; Fujita T; Hiroi S
Nihon Yakurigaku Zasshi; 2011 Jan; 137(1):43-50. PubMed ID: 21233588
[No Abstract] [Full Text] [Related]
17. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.
Noda Y; Miyoshi T; Oe H; Ohno Y; Nakamura K; Toh N; Kohno K; Morita H; Kusano K; Ito H
Cardiovasc Diabetol; 2013 Jan; 12():8. PubMed ID: 23298374
[TBL] [Abstract][Full Text] [Related]
18. Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.
Mizushige T; Kobori H; Nishijima Y; Yano Y; Sakata K; Hayakawa M; Nishiyama A
J Diabetes Res; 2015; 2015():517472. PubMed ID: 26380312
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
20. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs.
Lamine F; Lalubin F; Pitteloud N; Burnier M; Zanchi A
Swiss Med Wkly; 2016; 146():w14282. PubMed ID: 26922155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
